Seeking Alpha

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others ...

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in ...
PharmiWeb

MedPharm Welcomes Palvella Therapeutics’ Positive Topline Results from its Phase 3 study of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

DURHAM, N.C., March 17, 2026 - MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today welcomed the news that its partner, Palvella Therapeutics, Inc. ( ...

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic ...

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.
Medical Xpress

Macromolecular Substances: News and Research on Mechanistic Target of Rapamycin Complex 1

For most broken bones, bone cells regrow on their own while patients wear a cast or brace to keep the injury steady. But for complex or severe fractures, surgeons may intervene by placing grafts or ...